Skip to main content
. 2024 Jul 26;15:1388753. doi: 10.3389/fphar.2024.1388753

FIGURE 1.

FIGURE 1

Flow chart of clinical study participants. A total of 82 adults with gout flares were enrolled and randomly assigned to receive either WWXDD (25 mL, twice per day) or a low-dose of colchicine (0.5 mg twice per day) for a duration of 7 days. Among them, primary outcome data was completed by 78 participants (WWXDD n = 41, colchicine n = 37), while serologic tests at day 7 were completed by 44 participants (WWXDD n = 24, colchicine n = 20).